Nitric oxide, phosphodiesterase inhibition, and adaptation to hypoxic conditions.
Wilkins
M R
MR
Section on Clinical Pharmacology, Imperial College School of Medicine, Hammersmith Hospital, London W12 ONN, UK. m.wilkins@ic.ac.uk
Aldashev
A
A
Morrell
N W
NW
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000222:Adaptation, Physiological; D000532:Altitude Sickness / Q000209:etiology / Q000378:metabolism* / Q000517:prevention & control*; D000818:Animals; D001838:Bolivia; D006801:Humans; D006976:Hypertension, Pulmonary / Q000208:ethnology / Q000209:etiology / Q000378:metabolism* / Q000517:prevention & control*; D000860:Hypoxia / Q000150:complications / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism*; D010100:Oxygen / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D051381:Rats; D018609:Tibet
D010726:Phosphodiesterase Inhibitors; D009569:Nitric Oxide; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D010100:Oxygen